CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 5)

Average Co-Inventor Count = 6.8

ph-index = 4

Forward Citations = 50(Granted Patents)

Location History:

Loughton, GB (2001)
Buckhurst Hill, GB (2003 - 2010)
Harlow, GB (2010)
Epping, GB (2012)
Saffron Walden Essex, GB (2014)
Essex, GB (2012 - 2018)
Saffron Walden, GB (2013 - 2018)
Saffron, GB (2015 - 2018)

Company Filing History:

12 out of 2,405

Merck Sharp + Dohme Corp.

patents

7 out of 328

Chiesi Farmaceutici S.p.a.

patents

4 out of 1,535

Boehringer Ingelheim International Gmbh

patents

4. 4 out of 55

Merck Sharp + Dohme B.v.

where one patent can have more than one assignee

Years Active: 2001-2018

Loading Chart...

30 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 10155259 - FSH receptor antagonists (2018-12-18),

2. 10117860 - Aminoester derivatives (2018-11-06),

3. 10087176 - 3,5-dichloro,4-(3,4-(cyclo-)alkoxyphenyl)--2-carbonyloxy)ethyl)pyridine derivatives as PDE-4 inhibitors (2018-10-02),

4. 9931323 - Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use (2018-04-03),

5. 9809582 - Aminoester derivatives (2017-11-07),

6. 9763924 - Aminoester derivatives (2017-09-19),

7. 9636336 - Aminoester derivatives (2017-05-02),

8. 9328106 - Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use (2016-05-03),

9. 9199980 - Compounds (2015-12-01),

10. 9127007 - FSH receptor antagonists (2015-09-08),

11. 9044463 - FSH receptor antagonists (2015-06-02),

12. 9012644 - Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity (2015-04-21),

13. 8993757 - N-piperidin-4-yl derivatives (2015-03-31),

14. 8853193 - Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions (2014-10-07),

15. 8802663 - [object Object] (2014-08-12),

Title: Wesley Peter Blackaby: Pioneering Innovations in Medicine

Introduction: Wesley Peter Blackaby, a distinguished inventor hailing from Buckhurst Hill, GB, has made significant contributions to the world of inventors through his dedication to innovation and relentless pursuit of excellence. With 30 patents to his name, he is a prominent figure inspiring future generations of inventors to push the boundaries of what is possible.

Latest Patents:

1. FSH Receptor Antagonists: Wesley's invention of FSH receptor antagonists, with a focus on treating and preventing endometriosis, hormone-dependent breast cancer, contraception, and menstrual-related disorders, showcases his commitment to addressing critical healthcare needs.

2. Aminoester Derivatives: His compounds that function as phosphodiesterase 4 enzyme inhibitors and muscarinic M3 receptor antagonists highlight his innovative approach to preventing and treating respiratory tract diseases.

Career Highlights: Wesley's illustrious career includes noteworthy positions at renowned companies such as Merck Sharp & Dohme Corporation and Chiesi Farmaceutici S.p.a. His expertise in the pharmaceutical industry has been instrumental in driving forward medical advancements that benefit society.

Collaborations: Throughout his career, Wesley collaborated with esteemed coworkers like Richard Thomas Lewis and Leslie Joseph Street. Their collective efforts have led to groundbreaking inventions that have left a lasting impact on the field of medicine.

Conclusion: Wesley Peter Blackaby's remarkable journey as an inventor exemplifies the transformative power of innovation in the realm of medicine. His pioneering spirit and unwavering commitment to excellence continue to shape the future of healthcare, making him a truly inspirational figure in the world of inventors.

This text is generated by artificial intelligence and may not be accurate.